El índice h5 es el índice h de los artículos publicados en los últimos 5 años completos. Se trata del número mayor h en cuanto a que h artículos publicados entre 2014 - 2018 deben tener al menos h citas cada uno.ocultar
La mediana h5 de una publicación es el número mediano de citas de los artículos que componen el índice h5.ocultar
Título / AutorCitado porAño
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, AM Langkilde, ...
Diabetes, Obesity and Metabolism 16 (2), 159-169
3072014
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial
CS Kovacs, V Seshiah, R Swallow, R Jones, H Rattunde, HJ Woerle, ...
Diabetes, Obesity and Metabolism 16 (2), 147-158
2922014
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, ...
Diabetes, Obesity and Metabolism 16 (5), 467-477
2332014
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
JPH Wilding, V Woo, K Rohwedder, J Sugg, S Parikh, ...
Diabetes, Obesity and Metabolism 16 (2), 124-136
2132014
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
M Nauck
Diabetes, Obesity and Metabolism 18 (3), 203-216
1922016
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R Chilton, I Tikkanen, CP Cannon, S Crowe, HJ Woerle, UC Broedl, ...
Diabetes, Obesity and Metabolism 17 (12), 1180-1193
1902015
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)
GB Bolli, MC Riddle, RM Bergenstal, M Ziemen, K Sestakauskas, ...
Diabetes, Obesity and Metabolism 17 (4), 386-394
1872015
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls
CA Bannister, SE Holden, S Jenkins‐Jones, CL Morgan, JP Halcox, ...
Diabetes, Obesity and Metabolism 16 (11), 1165-1173
1812014
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
JF Yale, G Bakris, B Cariou, J Nieto, E David‐Neto, D Yue, E Wajs, ...
Diabetes, Obesity and Metabolism 16 (10), 1016-1027
1712014
Patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
R Ritzel, R Roussel, GB Bolli, L Vinet, C Brulle‐Wohlhueter, S Glezer, ...
Diabetes, Obesity and Metabolism 17 (9), 859-867
1652015
Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials
M Monami, I Dicembrini, C Nardini, I Fiordelli, E Mannucci
Diabetes, Obesity and Metabolism 16 (1), 38-47
1632014
Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials
M Monami, C Nardini, E Mannucci
Diabetes, Obesity and Metabolism 16 (5), 457-466
1622014
Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data
S Del Prato, M Nauck, S Durán‐Garcia, L Maffei, K Rohwedder, ...
Diabetes, Obesity and Metabolism 17 (6), 581-590
1612015
Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
F Zaccardi, DR Webb, ZZ Htike, D Youssef, K Khunti, MJ Davies
Diabetes, Obesity and Metabolism 18 (8), 783-794
1562016
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, ...
Diabetes, Obesity and Metabolism 16 (10), 984-993
1462014
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
J Rosenstock, A Jelaska, C Zeller, G Kim, UC Broedl, HJ Woerle, ...
Diabetes, Obesity and Metabolism 17 (10), 936-948
1422015
Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes
B Bode, K Stenlöf, S Harris, D Sullivan, A Fung, K Usiskin, G Meininger
Diabetes, Obesity and Metabolism 17 (3), 294-303
1422015
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
S Madsbad
Diabetes, Obesity and Metabolism 18 (4), 317-332
1412016
Diabetes and cancer: two diseases with obesity as a common risk factor
SK Garg, H Maurer, K Reed, R Selagamsetty
Diabetes, Obesity and Metabolism 16 (2), 97-110
1302014
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)
C Mathieu, HW Rodbard, B Cariou, Y Handelsman, A Philis‐Tsimikas, ...
Diabetes, Obesity and Metabolism 16 (7), 636-644
1262014
1 - 20
Las fechas y los recuentos de citas son estimados y se determinan de forma automática mediante un programa informático.